Company intelligence / Profile preview

Paradigm Therapeutics, Inc.

Mt Pleasant, South Carolina, United Statesparadigmtherapeutics.com ↗

Ownership: Private
Development stage: Phase 3

Overview

SD-101 (Zorblisa™) has completed Phase II and Phase III clinical trials for treating Epidermolysis Bullosa. The company is planning an NDA submission in the second half of 2025. The therapy has received Rare Pediatric Disease designation, Orphan Drug designation, and Breakthrough Therapy designation from the FDA.[1][3][4]

Therapeutic areas: DermatologyRare Diseases
Modalities: Topical therapies
Industry: Biotech

Drug pipeline

1 asset

allantoin

Beyond the preview

Go deeper on Paradigm Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paradigm Therapeutics, Inc..

Explore the full profile